Pay in 4 interest-free payments of $6.61 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine
Molecular Identity Developer Eli Lilly Brand Names Mounjaro (diabetes), Zepbound (obesity) Mechanism Dual GLP-1 and GIP receptor agonist FDA Status Approved (2022 diabetes, 2023 obesity) Administration Weekly subcutaneous GIP Receptor Pathway The GIP receptor activation in Tirzepatide provides different metabolic effects than glucagon: Incretin enhancement: GIP augments GLP-1's insulin-related signaling Adipose tissue effects: GIP receptor expression in fat tissue documented Tolerability profile: Some research suggests GIP may moderate GI effects Synergistic incretin signaling: Two incretin pathways vs
"Facial volume, primarily from fat, is key to a youthful appearance," she said
Macartney G, Zvonar, R., McDiarmid, S., Harris, B, and Laplante, J
US$ 27.72
US$ 22.34
US$ 24.19
US$ 23.84
US$ 26.51
US$ 22.31
US$ 23.18
US$ 27.50
US$ 24.32
US$ 29.30
US$ 27.69
US$ 28.27
US$ 20.93
US$ 26.93
US$ 27.95
